Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models. - Wikidata - awgldk - TriplyDB

Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.

Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.

http://www.wikidata.org/entity/Q37580312

about

Evolution of animal models in cancer vaccine development DNA vaccine for cancer immunotherapy A novel minigene scaffold for therapeutic cancer vaccines Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen.DNA vaccines, electroporation and their applications in cancer treatment MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model Immunotherapy of cancers comes of age.Vaccine Design: Replication-Defective Adenovirus Vectors.

P2860

Q28080739-333EFFEA-1B44-4E1D-B64C-B41443E9E1BC Q28080919-6831CE06-4C95-4F41-A115-C8B697B103D4 Q34418540-BE6AEC9E-2271-4438-83D8-6F029242A10C Q35542237-9548684A-4EDD-495E-B962-4C12825765AF Q35822301-65BE7CDC-81C2-4176-8B4C-BF11036B5368 Q36256459-D5C01359-270A-4F0A-949B-6D1914778434 Q36256568-1D482A86-7335-4405-B4F4-C5A47F168CB8 Q40099075-33F609C8-D3C8-44D1-938D-22136434E1D9 Q40801619-D804D5EA-8E6A-45DD-AE50-BCA0C0C3962D

P2860

Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.

http://www.wikidata.org/entity/Q37580312

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunogenicity and therapeutic ...... ER2/neu in preclinical models.

@en

Immunogenicity and therapeutic ...... ER2/neu in preclinical models.

@nl

type

label

Immunogenicity and therapeutic ...... ER2/neu in preclinical models.

@en

Immunogenicity and therapeutic ...... ER2/neu in preclinical models.

@nl

prefLabel

Immunogenicity and therapeutic ...... ER2/neu in preclinical models.

@en

Immunogenicity and therapeutic ...... ER2/neu in preclinical models.

@nl

P1433

Q37580312-C6D8775C-53E8-47A9-B1BE-BF590EE3BD30

P1476

Q37580312-7F6CECE7-2349-4780-B6EE-850517E4566B

P2093

Q37580312-498EB267-1C4F-433B-8E62-801F7D173DF8

Q37580312-8DD6EF46-19B7-459D-A931-F1F4E689BA23

Q37580312-AE41CC4E-2913-496F-A16D-740424E6CD9A

Q37580312-CA85996F-05E0-421D-B801-0F77E3592974

Q37580312-FA0F8C13-8BF1-496B-88ED-6C831343EB0D

P2860

Q37580312-07DEBDB4-E3EE-4BE8-AAC7-93D6AB1D69B3

Q37580312-16BB409E-777F-480C-8AF0-F3F1CF895D0E

Q37580312-19FBD1FC-A13E-4B76-AC2E-1796973A85F4

Q37580312-22ED7B32-8AB7-4F94-99FF-48869FBD0E31

Q37580312-28C9ED66-11D9-4938-9C4B-9F52A9965425

Q37580312-317F88F6-1607-4C9A-9F66-F3E5A1B7D0E4

Q37580312-43FDF2C6-45A7-44B8-A307-42F813A22D9B

Q37580312-49919936-5E43-4CBB-979F-BA1A386BCD85

Q37580312-4F596752-5C28-48FB-8B98-A264624F389E

Q37580312-55F2418C-7906-4BD0-B9B3-DB523307ECBE

P304

Q37580312-D3803855-C17B-404B-B787-645C755B44E4

P31

Q37580312-076FDB5B-7E53-44AA-9B67-BE9F5BDDA68C

P356

Q37580312-993641F0-B6A0-4C23-BE2D-186238548EE8

P433

Q37580312-56834F6D-4326-4BCA-889C-57452B6164A9

P478

Q37580312-2B35528B-113B-4320-AD29-0A94251CCFE1

P50

Q37580312-7BE7FE4A-1570-47A0-9542-2A02EEF6D500

P577

Q37580312-B99F005E-C3EB-4CB7-A83C-F543CDC92A5C

P5875

Q37580312-FCF48757-A632-481E-A19A-B30B2A5F49E8

P698

Q37580312-0E0DA9F7-0911-45A1-B89C-762316F1C572

P932

Q37580312-EDFF021E-5480-4FA2-9658-33D78034451F

P356

P1433

Human Gene Therapy

P1476

Immunogenicity and therapeutic ...... HER2/neu in preclinical models

@en

P2093

Daniela Peruzzi

http://www.w3.org/2001/XMLSchema#string

Gloria Koo

http://www.w3.org/2001/XMLSchema#string

Luigi Aurisicchio

http://www.w3.org/2001/XMLSchema#string

Nicola La Monica

http://www.w3.org/2001/XMLSchema#string

Wei-Zen Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

Dysregulation of cellular signaling by HER2/neu in breast cancer

Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA

Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines.

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.

Jump-starting the immune system: prime-boosting comes of age.

Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.

P304

121-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2013.103

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Gennaro Ciliberto

P577

2013-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258334413

http://www.w3.org/2001/XMLSchema#string

P698

24195644

http://www.w3.org/2001/XMLSchema#string

P932

3922413

http://www.w3.org/2001/XMLSchema#string